India has achieved a significant milestone in women’s healthcare with the successful validation of the country’s first indigenous Human Papillomavirus (HPV) test for cervical cancer screening. The breakthrough is expected to make early detection of cervical cancer more affordable and accessible, particularly for women living in rural and underserved regions where access to advanced diagnostic facilities remains limited.
Cervical cancer continues to be one of the leading causes of cancer-related illness and death among women in India. Medical experts emphasize that early detection is critical because cervical cancer can often be prevented or treated successfully when identified in its initial stages. However, screening rates in the country have remained relatively low due to the high cost of imported HPV tests and the infrastructure required to conduct them. The validation of an affordable, locally developed alternative is therefore being viewed as a major step forward in strengthening cancer prevention efforts.
The newly validated test was developed through a collaborative effort involving Indian researchers and healthcare institutions. Scientists from the All India Institute of Medical Sciences (AIIMS), institutes under the Indian Council of Medical Research (ICMR), and the World Health Organization’s International Agency for Research on Cancer (IARC) participated in the validation process. Their evaluation confirmed that the indigenous test meets internationally accepted standards for HPV screening and performs at levels comparable to globally recognized diagnostic tools.
The test, known as Truenat HPV-HR Plus, was developed by Goa-based company Molbio Diagnostics. It is designed to detect multiple high-risk HPV strains that are responsible for the majority of cervical cancer cases. Researchers noted that among the indigenous HPV DNA tests assessed during the study, Truenat HPV-HR Plus was the only assay that fully met international validation criteria, highlighting its reliability and effectiveness.
One of the most important advantages of the indigenous test is its affordability. Existing imported HPV screening tests can be expensive and are often unavailable in smaller healthcare centres. The new test is expected to reduce dependence on imported diagnostics while enabling large-scale screening programmes across the country. Healthcare experts believe that lower-cost testing could significantly increase screening coverage among women aged 30 years and above, the group most vulnerable to developing cervical cancer.
Human Papillomavirus is the leading cause of cervical cancer worldwide. Many HPV infections do not produce noticeable symptoms during their early stages, making routine screening essential. Detecting high-risk HPV infections before they progress to cancer allows healthcare providers to monitor patients, provide timely treatment, and prevent serious complications. Studies have consistently shown that regular HPV screening can substantially reduce both cervical cancer incidence and mortality.
The validation of the indigenous HPV test comes at a time when India is expanding efforts to eliminate cervical cancer through a combination of vaccination, awareness programmes, and improved screening services. Public health experts believe that widespread access to affordable HPV testing, coupled with ongoing vaccination initiatives, can play a crucial role in reducing the burden of cervical cancer and improving women’s health outcomes nationwide.
With the successful validation of this homegrown innovation, India has taken an important step toward strengthening preventive healthcare and making life-saving cervical cancer screening available to millions of women. The development not only demonstrates the country’s growing capabilities in medical research and diagnostics but also supports the broader goal of achieving equitable and accessible healthcare for all.
